vs
太平洋生物科学（ASMB）与AMREP CORP.（AXR）财务数据对比。点击上方公司名可切换其他公司
AMREP CORP.的季度营收约是太平洋生物科学的1.4倍（$14.6M vs $10.8M），AMREP CORP.净利率更高（21.6% vs -85.2%，领先106.8%），AMREP CORP.同比增速更快（93.8% vs 57.6%），AMREP CORP.自由现金流更多（$5.4M vs $-15.2M）
该公司是一家成立于2004年的美国生物科技企业，主要研发生产基因测序相关设备，同时也开展新型实时生物观测技术相关业务。目前拥有两大核心测序平台，分别是基于零模波导特性的单分子实时测序平台，以及结合天然核苷酸无痕连接技术的结合测序平台。
AMREP是一家总部位于美国新泽西州普林斯顿的企业，核心业务涵盖房地产与媒体服务领域。公司前身为美国地产石油公司，于1961年正式成立，在相关行业拥有六十余年的发展运营历史。
ASMB vs AXR — 直观对比
营收规模更大
AXR
是对方的1.4倍
$10.8M
营收增速更快
AXR
高出36.2%
57.6%
净利率更高
AXR
高出106.8%
-85.2%
自由现金流更多
AXR
多$20.6M
$-15.2M
损益表 — Q3 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $10.8M | $14.6M |
| 净利润 | $-9.2M | $3.1M |
| 毛利率 | — | — |
| 营业利润率 | -100.9% | 20.6% |
| 净利率 | -85.2% | 21.6% |
| 营收同比 | 57.6% | 93.8% |
| 净利润同比 | 4.3% | 338.9% |
| 每股收益（稀释后） | $-0.72 | $0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASMBAXR
| Q1 26 | — | $14.6M | ||
| Q4 25 | — | $9.4M | ||
| Q3 25 | $10.8M | $17.9M | ||
| Q2 25 | $9.6M | $11.2M | ||
| Q1 25 | $9.4M | $7.5M | ||
| Q4 24 | $7.4M | $11.9M | ||
| Q3 24 | $6.8M | $19.1M | ||
| Q2 24 | $8.5M | $19.5M |
净利润ASMBAXR
| Q1 26 | — | $3.1M | ||
| Q4 25 | — | $1.2M | ||
| Q3 25 | $-9.2M | $4.7M | ||
| Q2 25 | $-10.2M | $3.9M | ||
| Q1 25 | $-8.8M | $717.0K | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | $-9.6M | $4.1M | ||
| Q2 24 | $-11.2M | $4.1M |
营业利润率ASMBAXR
| Q1 26 | — | 20.6% | ||
| Q4 25 | — | 11.9% | ||
| Q3 25 | -100.9% | 34.4% | ||
| Q2 25 | -115.2% | 31.7% | ||
| Q1 25 | -105.5% | 5.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | -160.1% | 26.1% | ||
| Q2 24 | -143.0% | 23.9% |
净利率ASMBAXR
| Q1 26 | — | 21.6% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | -85.2% | 26.3% | ||
| Q2 25 | -105.9% | 34.8% | ||
| Q1 25 | -93.6% | 9.5% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | -140.4% | 21.3% | ||
| Q2 24 | -130.7% | 21.2% |
每股收益（稀释后）ASMBAXR
| Q1 26 | — | $0.58 | ||
| Q4 25 | — | $0.22 | ||
| Q3 25 | $-0.72 | $0.87 | ||
| Q2 25 | $-1.33 | $0.73 | ||
| Q1 25 | $-1.17 | $0.13 | ||
| Q4 24 | — | $0.75 | ||
| Q3 24 | $-1.51 | $0.76 | ||
| Q2 24 | $-1.98 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.5M | $50.0M |
| 总债务越低越好 | — | $21.0K |
| 股东权益账面价值 | $182.7M | $139.4M |
| 总资产 | $240.0M | $143.9M |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资ASMBAXR
| Q1 26 | — | $50.0M | ||
| Q4 25 | — | $44.6M | ||
| Q3 25 | $22.5M | $48.9M | ||
| Q2 25 | $24.0M | $39.5M | ||
| Q1 25 | $23.4M | $36.9M | ||
| Q4 24 | $38.3M | $40.1M | ||
| Q3 24 | $28.5M | $40.4M | ||
| Q2 24 | $19.2M | $29.7M |
总债务ASMBAXR
| Q1 26 | — | $21.0K | ||
| Q4 25 | — | $23.0K | ||
| Q3 25 | — | $25.0K | ||
| Q2 25 | — | $26.0K | ||
| Q1 25 | — | $29.0K | ||
| Q4 24 | — | $32.0K | ||
| Q3 24 | — | $34.0K | ||
| Q2 24 | — | $35.0K |
股东权益ASMBAXR
| Q1 26 | — | $139.4M | ||
| Q4 25 | — | $136.0M | ||
| Q3 25 | $182.7M | $134.7M | ||
| Q2 25 | $18.1M | $130.0M | ||
| Q1 25 | $27.1M | $126.0M | ||
| Q4 24 | $33.4M | $125.1M | ||
| Q3 24 | $26.0M | $122.2M | ||
| Q2 24 | $34.7M | $118.0M |
总资产ASMBAXR
| Q1 26 | — | $143.9M | ||
| Q4 25 | — | $140.1M | ||
| Q3 25 | $240.0M | $140.7M | ||
| Q2 25 | $80.8M | $133.8M | ||
| Q1 25 | $99.0M | $128.9M | ||
| Q4 24 | $119.2M | $129.1M | ||
| Q3 24 | $100.3M | $127.0M | ||
| Q2 24 | $115.3M | $122.8M |
负债/权益比ASMBAXR
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.1M | $5.4M |
| 自由现金流经营现金流 - 资本支出 | $-15.2M | $5.4M |
| 自由现金流率自由现金流/营收 | -140.7% | 37.0% |
| 资本支出强度资本支出/营收 | 0.4% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | — | $20.2M |
8季度趋势，按日历期对齐
经营现金流ASMBAXR
| Q1 26 | — | $5.4M | ||
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $-15.1M | $9.5M | ||
| Q2 25 | $-16.8M | $10.2M | ||
| Q1 25 | $-23.4M | $-3.2M | ||
| Q4 24 | $-51.1M | $-182.0K | ||
| Q3 24 | $-15.2M | $10.7M | ||
| Q2 24 | $-17.1M | $10.7M |
自由现金流ASMBAXR
| Q1 26 | — | $5.4M | ||
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $-15.2M | $9.5M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | — | $-3.3M | ||
| Q4 24 | $-51.1M | $-268.0K | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | $-17.1M | $10.3M |
自由现金流率ASMBAXR
| Q1 26 | — | 37.0% | ||
| Q4 25 | — | -45.9% | ||
| Q3 25 | -140.7% | 53.2% | ||
| Q2 25 | — | 86.4% | ||
| Q1 25 | — | -43.4% | ||
| Q4 24 | -695.2% | -2.3% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | -200.6% | 52.5% |
资本支出强度ASMBAXR
| Q1 26 | — | 0.1% | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | 0.4% | 0.1% | ||
| Q2 25 | 0.0% | 5.2% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.4% | 0.7% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.2% | 2.3% |
现金转化率ASMBAXR
| Q1 26 | — | 1.72× | ||
| Q4 25 | — | -3.54× | ||
| Q3 25 | — | 2.03× | ||
| Q2 25 | — | 2.63× | ||
| Q1 25 | — | -4.51× | ||
| Q4 24 | — | -0.05× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | — | 2.59× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
